The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...
Cyclo Therapeutics, Inc. ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback